14C-ciraparantag

Ciraparantag (formerly PER977) is a small, synthetic, water-soluble molecule developed by Perosphere Pharmaceuticals (a subsidiary of AMAG Pharmaceuticals) as a broad-spectrum anticoagulant reversal agent. It is designed to rapidly reverse the effects of various anticoagulants, including unfractionated heparin, low-molecular-weight heparin (LMWH), fondaparinux, and direct oral anticoagulants (DOACs) such as factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and the factor IIa inhibitor dabigatran. The molecule functions through non-covalent charge-charge interactions, binding to the anticoagulant molecules and preventing them from interacting with their biological targets, thereby restoring normal coagulation. The 14C-labeled version, 14C-ciraparantag, is specifically utilized in clinical pharmacology studies, such as mass balance and absorption, metabolism, and excretion (AME) trials, to track the drug's metabolic pathways and disposition in human subjects.

Other names

14C-labeled ciraparantagradiolabeled ciraparantag